A5053818648- Cancer Genomics and Diagnostics
- Pancreatic and Hepatic Oncology Research
- Genetic factors in colorectal cancer
- Renal cell carcinoma treatment
- DNA Repair Mechanisms
- Hepatocellular Carcinoma Treatment and Prognosis
- Neuroendocrine Tumor Research Advances
- Colorectal Cancer Treatments and Studies
- Epigenetics and DNA Methylation
- Adenosine and Purinergic Signaling
- RNA and protein synthesis mechanisms
- Diverticular Disease and Complications
- Cell Adhesion Molecules Research
- PI3K/AKT/mTOR signaling in cancer
- Esophageal Cancer Research and Treatment
- Melanoma and MAPK Pathways
- BRCA gene mutations in cancer
- Protein Kinase Regulation and GTPase Signaling
- Gastrointestinal disorders and treatments
- Innovations in Medical Education
- Liver physiology and pathology
- Esophageal and GI Pathology
- Hepatitis B Virus Studies
- Caveolin-1 and cellular processes
- Organ Transplantation Techniques and Outcomes
University of Toronto
2005-2024
Sunnybrook Health Science Centre
2023-2024
Memorial Sloan Kettering Cancer Center
2024
Medical College of Wisconsin
2024
Princess Margaret Cancer Centre
2020-2023
University Health Network
2020-2022
Western University
2018
London Health Sciences Centre
2018
Lunenfeld-Tanenbaum Research Institute
2006-2010
Mount Sinai Hospital
2006-2010
Modified FOLFIRINOX (mFFX) and gemcitabine/nab-paclitaxel (GnP) remain standard first-line options for patients with advanced pancreatic ductal adenocarcinoma (PDAC). Human equilibrative nucleoside transporter 1 (hENT1) was hypothesized to be a biomarker of gemcitabine in the adjuvant setting, conflicting results. In this study, we explore hENT1 mRNA expression as predictive PDAC.COMPASS prospective observational trial PDAC. A biopsy required prior initiating chemotherapy, determined by...
Epidermal growth factor receptor (EGFR) T790M mutations can be detected in the circulating tumour DNA from plasma of patients with non-small cell lung cancer (NSCLC) to triage for osimertinib eligibility and monitor longitudinally development T790M-mediated resistance.Using droplet digital PCR (ddPCR), we examined EGFR status 343 sequential NSCLC correlated mutational demographic clinical features. Where available, serial blood test results were assessed identify triggers timing repeat...
Germline mutations in the mismatch repair genes lead to Lynch syndrome/ HNPCC, and genetic testing is offered identify individuals at risk of developing this disease. About a third all alterations detected gene MutL homolog 1 (MLH1) are missense variants. The majority these variants equivocal clinical significance. In report, we investigate molecular basis pathogenicity three localized distinct functional domains. Our results demonstrate that MLH1 p.Arg265Cys (c.793C>T) p.Lys618Ala...
Hepatocellular carcinoma (HCC) recurs after liver transplantation (LT) in ~17% of patients. We aimed to retrospectively compare the outcomes patients treated with different tyrosine kinase inhibitors (TKIs) for recurrent HCC post-LT.
Gender equity has historically been a challenge within gastroenterology.The Canadian Association of Gastroenterology (CAG) developed survey to identify issues pertaining and gender faced by its membership determine areas action.In 2014, the was emailed all 1155 CAG members, data were analyzed using statistical methods.One hundred eleven members responded survey. Of those, 52% male, 75% between 26 45 years age, 55% in their first decade practice. More males held status full professor (21%...
We would like to thank Boyd and colleagues for their thoughtful comments on our work demonstrating hENT1 as a predictive biomarker gemcitabine nab-paclitaxel (GnP) in advanced pancreatic ductal carcinoma (PDAC) the COMPASS trial (NCT02750657; ref. 1). These findings will be further validated ongoing phase II PASS-01 (ref. 2; NCT04469556), randomizing patients either modified FOLFIRINOX (mFFX) or GnP.The authors correctly highlight RNA expression after laser capture microdissection (LCM)...
<div>AbstractPurpose:<p>Modified FOLFIRINOX (mFFX) and gemcitabine/nab-paclitaxel (GnP) remain standard first-line options for patients with advanced pancreatic ductal adenocarcinoma (PDAC). Human equilibrative nucleoside transporter 1 (hENT1) was hypothesized to be a biomarker of gemcitabine in the adjuvant setting, conflicting results. In this study, we explore hENT1 mRNA expression as predictive PDAC.</p>Experimental Design:<p>COMPASS prospective observational...
4011 Background: Human equilibrative nucleoside transporter 1 (hENT1) belongs to a family of transporters critical entry gemcitabine into cells. The prognostic and predictive characteristics this biomarker in pancreatic ductal adenocarcinoma (PDAC) have primarily been evaluated by immunohistochemistry, with conflicting results. We explored the impact hENT1 gene expression Comprehensive Molecular Characterization Advanced Ductal Pancreas Adenocarcinoma for Better Treatment Selection (COMPASS)...
430 Background: Familial pancreatic cancer (FPC) is broadly defined as kindreds with at least a pair of first-degree relatives ductal adenocarcinoma (PDA). The role DNA damage response agents, including platinum has not been well studied in this patient population. Methods: In retrospective analysis, treatment details and clinical outcomes were analyzed pts FPC advanced, unresectable or recurrent disease enrolled the Ontario Pancreatic Cancer Study database. primary outcome, overall survival...
396 Background: BRCA1/2 and PALB2 are genes critical to the faithful repair of double strand breaks through homologous recombination (HRR) pathway. Alterations in these serve as predictive biomarkers both platinum PARP inhibitors. Ataxia-telangiectasia mutated ( ATM) is also indirectly involved HRR; however, its role a biomarker DNA damage response agents debated. Herein we evaluated genomic characteristics clinical outcomes patients with ATM alterations on Comprehensive Molecular...
Review on STK11 (serine/threonine kinase 11), with data DNA, the protein encoded, and where gene is implicated.
<p>Figure S1. hENT1 expression by modified Moffitt subtypes Figure S2. OS in GnP cohort stratified and Classifier</p>
<div>AbstractPurpose:<p>Modified FOLFIRINOX (mFFX) and gemcitabine/nab-paclitaxel (GnP) remain standard first-line options for patients with advanced pancreatic ductal adenocarcinoma (PDAC). Human equilibrative nucleoside transporter 1 (hENT1) was hypothesized to be a biomarker of gemcitabine in the adjuvant setting, conflicting results. In this study, we explore hENT1 mRNA expression as predictive PDAC.</p>Experimental Design:<p>COMPASS prospective observational...
<p>Figure S1. hENT1 expression by modified Moffitt subtypes Figure S2. OS in GnP cohort stratified and Classifier</p>